These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30929560)

  • 1. Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.
    Richter F; Seifert O; Herrmann A; Pfizenmaier K; Kontermann RE
    MAbs; 2019; 11(4):653-665. PubMed ID: 30929560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity.
    Richter F; Zettlitz KA; Seifert O; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann RE
    MAbs; 2019 Jan; 11(1):166-177. PubMed ID: 30252601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
    Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
    Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE; Münkel S; Neumeyer J; Müller D; Branschädel M; Scheurich P; Pfizenmaier K
    J Immunother; 2008 Apr; 31(3):225-34. PubMed ID: 18317365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.
    Goodall LJ; Ovecka M; Rycroft D; Friel SL; Sanderson A; Mistry P; Davies ML; Stoop AA
    PLoS One; 2015; 10(9):e0137065. PubMed ID: 26352810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
    Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS
    MAbs; 2016; 8(4):761-74. PubMed ID: 26963639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.
    Zettlitz KA; Lorenz V; Landauer K; Münkel S; Herrmann A; Scheurich P; Pfizenmaier K; Kontermann R
    MAbs; 2010; 2(6):639-47. PubMed ID: 20935477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
    Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
    BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.
    Steeland S; Puimège L; Vandenbroucke RE; Van Hauwermeiren F; Haustraete J; Devoogdt N; Hulpiau P; Leroux-Roels G; Laukens D; Meuleman P; De Vos M; Libert C
    J Biol Chem; 2015 Feb; 290(7):4022-37. PubMed ID: 25538244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.
    Pleckaityte M; Zvirbliene A; Sezaite I; Gedvilaite A
    Microb Cell Fact; 2011 Dec; 10():109. PubMed ID: 22171920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of TNFR1 reduces osteoclast numbers and is differentiated from anti-TNF in a LPS-driven model of inflammatory bone loss.
    Espirito Santo AI; Ersek A; Freidin A; Feldmann M; Stoop AA; Horwood NJ
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1145-1150. PubMed ID: 26208457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
    Abe Y; Yoshikawa T; Inoue M; Nomura T; Furuya T; Yamashita T; Nagano K; Nabeshi H; Yoshioka Y; Mukai Y; Nakagawa S; Kamada H; Tsutsumi Y; Tsunoda S
    Biomaterials; 2011 Aug; 32(23):5498-504. PubMed ID: 21546081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation.
    Richter F; Williams SK; John K; Huber C; Vaslin C; Zanker H; Fairless R; Pichi K; Marhenke S; Vogel A; Dhaen MA; Herrmann S; Herrmann A; Pfizenmaier K; Bantel H; Diem R; Kontermann RE; Fischer R
    Front Immunol; 2021; 12():705485. PubMed ID: 34305946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
    Scallon B; Cai A; Radewonuk J; Naso M
    Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF receptor II fusion protein with tandemly repeated Fc domains.
    Nagashima H; Kaneko K; Yamanoi A; Motoi S; Konakahara S; Kohroki J; Masuho Y
    J Biochem; 2011 Mar; 149(3):337-46. PubMed ID: 21278157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity.
    Ji X; Lu W; Zhou H; Han D; Yang L; Wu H; Li J; Liu H; Zhang J; Cao P; Zhang S
    Appl Microbiol Biotechnol; 2013 Oct; 97(19):8547-58. PubMed ID: 23324801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.